Can a Two-Drug immune attack shrink Hard-to-Treat pancreatic tumors?
NCT ID NCT07765836
First seen Aug 14, 2026 · Last updated Aug 14, 2026
Summary
This phase 2 trial is testing whether combining two immunotherapy drugs—vilastobart and retifanlimab—can shrink tumors in people with metastatic pancreatic cancer that has a BRCA1, BRCA2, or PALB2 gene mutation. Participants receive both drugs by IV infusion over several months. The main goal is to see how many patients experience tumor shrinkage, with additional monitoring of progression-free and overall survival.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- vilastobart (XTX101) combined with retifanlimab
- What this could lead to
- If this combination works, it could offer a new treatment option for people with BRCA- or PALB2-mutated pancreatic cancer, potentially shrinking tumors and extending survival.
- What could go wrong
- This is an early-phase, single-arm trial with only 40 participants, so results may not be conclusive. The combination may cause immune-related side effects, and not all patients may respond.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC PANCREATIC ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Massachusetts General Hospital
Boston, Massachusetts, 02114, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a targeted antibody give pancreatic cancer chemo a boost?
- Can three common drugs boost chemotherapy against pancreatic cancer?
- Can High-Dose vitamin c boost chemo against pancreatic cancer?
- AI trained on thousands of pancreatic cancer cases could revolutionize diagnosis
- Could a nerve zap stop cancer wasting? early trial tests device for cachexia
- New drug combo aims to shrink Hard-to-Treat pancreatic and ovarian tumors